OPNTのニュース
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2022 Results - Earnings Call Transcript 2022/08/12 13:10:08 Seeking Alpha
Opiant Pharmaceuticals, Inc. (NASDAQ:NASDAQ:OPNT) Q2 2022 Earnings Conference Call August 11, 2022 04:30 PM ET Company Participants Ben Atkins - VP Communications and Investor Relations…
Opiant Pharmaceuticals GAAP EPS of -$2.31 misses by $0.95, revenue of $3.89M misses by $0.77M 2022/08/11 20:39:04 Seeking Alpha
Opiant Pharmaceuticals press release (NASDAQ:OPNT): Q2 GAAP EPS of -$2.31 misses by $0.95.Revenue of $3.89M (-65.5% Y/Y) misses by $0.77M.
Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update 2022/08/11 20:05:00 GlobeNewswire
SANTA MONICA, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months and six months ended June 30, 2022, and provided a corporate update. Recent highlights include:
Opiant Pharmaceuticals Q2 Earnings Preview (NASDAQ:OPNT) 2022/08/10 21:35:43 Seeking Alpha
Opiant Pharmaceuticals (OPNT) is scheduled to announce Q2 earnings results on Thursday, August 11th, after market close.The consensus EPS Estimate is -$1.36 and the consensus…
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful 2022/08/09 13:08:37 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy Mersana Therapeutics Inc (NASDAQ: MRSN ) announced a global collaboration that provides GSK plc (NYSE: GSK ) an exclusive option to co-develop and commercialize XMT-2056. Mersana will receive an upfront option purchase fee of $100 million. Mersana is also eligible to receive up to $1.36 billion in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option. Mersana has retained options to profit-share and to co-promote in the U.S. Clearside Biomedical Secures Non-Dilutive fUNDING fROM HealthCare Royalty Partners Clearside Biomedical Inc (NASDAQ: CLSD ) has entered into a Royalty Interest Purchase and Sale Agreement with HealthCare Royalty Partners. Under the terms of the agreement, Clearside will receive an initial payment of $32.5 million . At the same time, an additional $12.5 million will be deposited in an escrow account to be released to Clearside upon attainment of a pre-specified sales milestone for XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use.
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2022 Results - Earnings Call Transcript 2022/08/12 13:10:08 Seeking Alpha
Opiant Pharmaceuticals, Inc. (NASDAQ:NASDAQ:OPNT) Q2 2022 Earnings Conference Call August 11, 2022 04:30 PM ET Company Participants Ben Atkins - VP Communications and Investor Relations…
Opiant Pharmaceuticals GAAP EPS of -$2.31 misses by $0.95, revenue of $3.89M misses by $0.77M 2022/08/11 20:39:04 Seeking Alpha
Opiant Pharmaceuticals press release (NASDAQ:OPNT): Q2 GAAP EPS of -$2.31 misses by $0.95.Revenue of $3.89M (-65.5% Y/Y) misses by $0.77M.
Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update 2022/08/11 20:05:00 GlobeNewswire
SANTA MONICA, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months and six months ended June 30, 2022, and provided a corporate update. Recent highlights include:
Opiant Pharmaceuticals Q2 Earnings Preview (NASDAQ:OPNT) 2022/08/10 21:35:43 Seeking Alpha
Opiant Pharmaceuticals (OPNT) is scheduled to announce Q2 earnings results on Thursday, August 11th, after market close.The consensus EPS Estimate is -$1.36 and the consensus…
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful 2022/08/09 13:08:37 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy Mersana Therapeutics Inc (NASDAQ: MRSN ) announced a global collaboration that provides GSK plc (NYSE: GSK ) an exclusive option to co-develop and commercialize XMT-2056. Mersana will receive an upfront option purchase fee of $100 million. Mersana is also eligible to receive up to $1.36 billion in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option. Mersana has retained options to profit-share and to co-promote in the U.S. Clearside Biomedical Secures Non-Dilutive fUNDING fROM HealthCare Royalty Partners Clearside Biomedical Inc (NASDAQ: CLSD ) has entered into a Royalty Interest Purchase and Sale Agreement with HealthCare Royalty Partners. Under the terms of the agreement, Clearside will receive an initial payment of $32.5 million . At the same time, an additional $12.5 million will be deposited in an escrow account to be released to Clearside upon attainment of a pre-specified sales milestone for XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use.
Opiant, Aptar expand collaboration for the making of Unidose nasal spray for OPNT003 2022/06/08 20:17:32 Seeking Alpha
Opiant Pharmaceuticals (OPNT) on Wednesday said it would expand its long-term collaboration with Aptar Pharma for the making of Aptar''s nasal Unidose device to be used in the production…
Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene 2022/06/08 20:05:00 GlobeNewswire
Long-term agreement includes a €2 million (approximately $2.1 million) investment by Opiant to expand Aptar’s production in support of OPNT003 Long-term agreement includes a €2 million (approximately $2.1 million) investment by Opiant to expand Aptar’s production in support of OPNT003
Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q1 2022 Results - Earnings Call Transcript 2022/05/14 22:34:06 Seeking Alpha
Opiant Pharmaceuticals, Inc. (NASDAQ:NASDAQ:OPNT) Q1 2022 Results Conference Call May 10, 2022 04:30 PM ET Company Participants Ben Atkins - Vice President, Communications and Investor…